Abstract
Advanced glycation end products (AGEs) are formed from the non-enzymatic reaction between reducing sugars and amine residues on proteins, lipoproteins or nucleic acids. AGEs are found on long-lived proteins and their tissue accumulation is associated with normal ageing. The formation of AGEs can be accelerated in certain pathological conditions such as diabetes where hyperglycaemia is present. AGE modification of proteins can lead to alterations of normal function by binding to intracellular or extracellular cell components, or through receptor binding. This consequently can initiate a cascade of events, which includes the activation of signal transduction pathways, which activate inflammatory responses causing tissue damage. Such tissue injury contributes to the development of microvascular complications and is of particular relevance in diabetes where interventions to reduce the accumulation of AGEs is desirable.
Keywords: superoxide dismutase, hyperglycaemia, reactive oxygen species, type 2 diabetes, AGE receptors
Protein & Peptide Letters
Title: Advanced Glycation: Implications in Tissue Damage and Disease
Volume: 15 Issue: 4
Author(s): Anna Gasser and Josephine M. Forbes
Affiliation:
Keywords: superoxide dismutase, hyperglycaemia, reactive oxygen species, type 2 diabetes, AGE receptors
Abstract: Advanced glycation end products (AGEs) are formed from the non-enzymatic reaction between reducing sugars and amine residues on proteins, lipoproteins or nucleic acids. AGEs are found on long-lived proteins and their tissue accumulation is associated with normal ageing. The formation of AGEs can be accelerated in certain pathological conditions such as diabetes where hyperglycaemia is present. AGE modification of proteins can lead to alterations of normal function by binding to intracellular or extracellular cell components, or through receptor binding. This consequently can initiate a cascade of events, which includes the activation of signal transduction pathways, which activate inflammatory responses causing tissue damage. Such tissue injury contributes to the development of microvascular complications and is of particular relevance in diabetes where interventions to reduce the accumulation of AGEs is desirable.
Export Options
About this article
Cite this article as:
Gasser Anna and Forbes M. Josephine, Advanced Glycation: Implications in Tissue Damage and Disease, Protein & Peptide Letters 2008; 15 (4) . https://dx.doi.org/10.2174/092986608784246515
DOI https://dx.doi.org/10.2174/092986608784246515 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes
Current Drug Targets The Predominant microRNAs in β-cell Clusters for Insulin Regulation and Diabetic Control
Current Drug Targets Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Novel Therapeutic Agents for Hyperuricemia in Patients with Gout
Current Drug Therapy Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective
Current Diabetes Reviews Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies The Metabolic Syndrome and the Relevance of Nutrients for its Onset
Recent Patents on Biotechnology Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Achilles Tendon in Diabetes
Current Diabetes Reviews Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus
Current Drug Targets